Search research articles
Contact Us
Filters
Showing results (21-30 of 27) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 27 results.
Leukemia & Lymphoma
|
October 1, 2016
Ganetespib, an HSP90 inhibitor, kills Epstein-Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood
Amber Shatzer, Mir A Ali, Mayra Chavez, et al.
Plos One
|
December 7, 2013
Altered antibody profiles against common infectious agents in chronic disease
Peter D Burbelo, Kathryn H Ching, Caryn G Morse, et al.
Blood
|
December 1, 2020
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines
Christopher Pleyer, Mir A Ali, Jeffrey I Cohen, et al.
Blood Advances
|
February 14, 2022
BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL
Christopher Pleyer, Kerry J Laing, Mir A Ali, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 9, 2022
Comparison of Levels of Nasal, Salivary, and Plasma Antibody to Severe Acute Respiratory Syndrome Coronavirus 2 During Natural Infection and After Vaccination
Jeffrey I Cohen, Lesia Dropulic, Kening Wang, et al.
The Journal of the American Osteopathic Association
|
August 30, 2016
Education and Communication in an Interprofessional Antimicrobial Stewardship Program
Pamela A Foral, Jennifer M Anthone, Christopher J Destache, et al.
The Journal of Infectious Diseases
|
March 15, 2021
Serum and Cervicovaginal Fluid Antibody Profiling in Herpes Simplex Virus-Seronegative Recipients of the HSV529 Vaccine
Kening Wang, Lesia Dropulic, Joel Bozekowski, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 27) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 27 results.
Leukemia & Lymphoma
|
October 1, 2016
Ganetespib, an HSP90 inhibitor, kills Epstein-Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood
Amber Shatzer, Mir A Ali, Mayra Chavez, et al.
Plos One
|
December 7, 2013
Altered antibody profiles against common infectious agents in chronic disease
Peter D Burbelo, Kathryn H Ching, Caryn G Morse, et al.
Blood
|
December 1, 2020
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines
Christopher Pleyer, Mir A Ali, Jeffrey I Cohen, et al.
Blood Advances
|
February 14, 2022
BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL
Christopher Pleyer, Kerry J Laing, Mir A Ali, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 9, 2022
Comparison of Levels of Nasal, Salivary, and Plasma Antibody to Severe Acute Respiratory Syndrome Coronavirus 2 During Natural Infection and After Vaccination
Jeffrey I Cohen, Lesia Dropulic, Kening Wang, et al.
The Journal of the American Osteopathic Association
|
August 30, 2016
Education and Communication in an Interprofessional Antimicrobial Stewardship Program
Pamela A Foral, Jennifer M Anthone, Christopher J Destache, et al.
The Journal of Infectious Diseases
|
March 15, 2021
Serum and Cervicovaginal Fluid Antibody Profiling in Herpes Simplex Virus-Seronegative Recipients of the HSV529 Vaccine
Kening Wang, Lesia Dropulic, Joel Bozekowski, et al.
Page
of 3